Join us November 6th for the International CML Foundation Forum at AORTIC

Join us November 6th for the International CML Foundation Forum at AORTIC

The African Organization for Research and Training in Cancer conference (AORTIC), happening November 5–8, 2019 brings together leading cancer specialists from around the world.

During the conference, attendees are invited to join The Max Foundation and the International and Chronic Myeloid Leukemia Foundation (iCMLf) for an interactive session for African Physicians Treating CML.

When:
Wednesday, November 6 from 5–8 PM at the Radisson Blu Hotel, adjacent to the AORTIC conference center in Maputo, Mozambique.

Discussion Topics:

In this session leading physicians and experts will discuss the following:

  • Monitoring CML in a low-resource setting
  • Responsible management in the era of 5 TIKs
  • Meet the expert: Small group discussions

Get to know the speakers:

This is an opportunity to join in-person to learn from the experts and exchange valuable ideas and transformative practices. Light dinner refreshments will be served.

To reserve your place please email Arlene Harris-Buchan.

Download the invitation here.

See All News

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

Related Articles

  • New study confirms an excellent survival rate of cancer patients in a medication donation program

    New study confirms an excellent survival rate of cancer patients in a medication donation program

    A new study led by Boston University School of Public Health, The Max Foundation, and Novartis Oncology found that chronic myeloid leukemia (CML) patients taking first-line treatment in low- and middle-income countries (LMICs) as part of the Glivec International Patient Assistance Program (GIPAP) have survival rates that compare favorably to those of CML patients receiving treatment in high-income countries.

  • Pat Garcia-Gonzalez Named Finalist for UICC’s CEO Award

    Pat Garcia-Gonzalez Named Finalist for UICC’s CEO Award

    The Max Foundation is proud to announce that our Chief Executive Officer Pat Garcia-Gonzalez has been named a finalist for the Union for International Cancer Control (UICC)’s CEO Award!

  • The Max Foundation and Tanner Pharma partner on innovative drug distribution model

    The Max Foundation and Tanner Pharma Group have partnered to create an innovative distribution model to deliver oncology products to patients in need.